{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:31:22Z","timestamp":1761895882970},"reference-count":122,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,6,28]],"date-time":"2014-06-28T00:00:00Z","timestamp":1403913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Mantle cell lymphoma is a heterogeneous subtype of non\u2010Hodgkin lymphoma. Conventional treatment with immunochemotherapy followed by autologous stem cell transplantation or intensive immunochemotherapy alone has improved outcomes, but the disease remains incurable. Recent advances in basic and translational research have significantly enhanced our understanding of disease pathogenesis and have sparked the development of novel therapies. Novel agents include the proteasome inhibitor bortezomib, the immunomodulatory agent lenalidomide, the phosphatidylinositol\u20104,5\u2010bisphosphate 3\u2010kinase pathway inhibitor idelalisib and the Bruton tyrosine kinase inhibitor ibrutinib. Preliminary results from clinical trials, especially from studies of ibrutinib, have proven these agents to be effective. In ongoing studies, these agents are being integrated into conventional immunochemotherapy regimens to hopefully improve patient outcomes.<\/jats:p>","DOI":"10.1111\/bjh.13000","type":"journal-article","created":{"date-parts":[[2014,6,28]],"date-time":"2014-06-28T06:33:46Z","timestamp":1403937226000},"page":"3-18","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Current regimens and novel agents for mantle cell lymphoma"],"prefix":"10.1111","volume":"167","author":[{"given":"Yiming","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Romaguera","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,6,28]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe078203"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-296913"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.00093.x"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3116"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2002.00551.x"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70062-6"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.088377"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(00)00255-2"},{"key":"e_1_2_11_11_1","first-page":"2757","article-title":"Ofatumumab (OFA) is a novel anti\u2010CD20 monoclonal antibody (mAb) with improved anti\u2010tumor activity in vitro and in vivo in mantle cell lymphoma (MCL) pre\u2010clinical models","volume":"120","author":"Barth M.J.","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.608445"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt070"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11267"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.7055"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-523845"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt139"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.07.028"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.2554"},{"key":"e_1_2_11_20_1","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1200\/jco.2013.31.15_suppl.8520","article-title":"Updated results of a phase I first\u2010in\u2010human study of the BCL\u20102 inhibitor ABT\u2010199 (GDC\u20100199) in patients with relapsed\/refractory non\u2010Hodgkin lymphoma (NHL)","volume":"31","author":"Davids M.S.","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-370320"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117010"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3883"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds643"},{"key":"e_1_2_11_25_1","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1182\/blood.V120.21.3672.3672","article-title":"Bortezomib plus DA\u2010EPOCH\u2010R induction therapy followed by maintenance bortezomib versus observation in newly diagnosed mantle cell lymphoma","volume":"120","author":"Dunleavy K.","year":"2012","journal-title":"Blood"},{"key":"e_1_2_11_26_1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V120.21.55.55","article-title":"A phase II multicenter study of the histone deacetylase inhibitor (HDACi) abexinostat (PCI\u201024781) in relapsed\/refractory follicular lymphoma (FL) and mantle cell lymphoma (MCL)","volume":"120","author":"Evens A.M.","year":"2012","journal-title":"Blood"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3419"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_11_29_1","first-page":"2748","article-title":"Rituximab, lenalidomide, and bortezomib in the first\u2010line or second\u2010line treatment of patients with mantle cell lymphoma a phase I\/II trial","volume":"120","author":"Flinn I.W.","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_11_31_1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1182\/blood.V116.21.964.964","article-title":"The Btk inhibitor, PCI\u201032765, induces durable responses with minimal toxicity in patients with relapsed\/refractory B\u2010cell malignancies: results from a phase I study","volume":"116","author":"Fowler N.","year":"2010","journal-title":"Blood"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-314708"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.047357"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-236570"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09174.x"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn656"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2835"},{"key":"e_1_2_11_40_1","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1182\/blood.V118.21.2707.2707","article-title":"Eleven\u2010year follow\u2010up of idiotype vaccine and DA\u2010EPOCH\u2010rituximab in untreated mantle cell lymphoma: correlation of survival with idiotype immune response","volume":"118","author":"Grant C.","year":"2011","journal-title":"Blood"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348367"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07626.x"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.162"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3702"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328484"},{"key":"e_1_2_11_47_1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood.V120.21.151.151","article-title":"Alternating courses of 3 \u00d7 CHOP and 3 \u00d7 DHAP plus rituximab followed by a high dose ARA\u2010C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL younger trial of the european mantle cell lymphoma network (MCL net)","volume":"120","author":"Hermine O.","year":"2012","journal-title":"Blood"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7977"},{"key":"e_1_2_11_49_1","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.V118.21.2697.2697","article-title":"Temsirolimus in combination with bendamustine and rituximab for the Treatment of relapsed mantle cell and follicular lymphoma: report on an ongoing phase I\/II trial","volume":"118","author":"Hess G.","year":"2011","journal-title":"Blood"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-352492"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm608"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.5.1288"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.9438"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1377-y"},{"key":"e_1_2_11_56_1","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1182\/blood.V120.21.3661.3661","article-title":"Phase I trial of rituximab, cladribine and temsirolimus (RCT) for initial therapy of mantle cell lymphoma","volume":"120","author":"Inwards D.J.","year":"2012","journal-title":"Blood"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr035"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61272"},{"key":"e_1_2_11_59_1","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1182\/blood.V118.21.2700.2700","article-title":"Lenalidomide, bendamustine, and rituximab as first\u2010line therapy for patients > 65 Years with mantle cell lymphoma: results from the phase I portion of the nordic lymphoma group MCL4 (LENA\u2010BERIT) trial","volume":"118","author":"Jerkeman M.","year":"2011","journal-title":"Blood"},{"key":"e_1_2_11_60_1","first-page":"153","article-title":"Mature results from ECOG study E1405\u2010A phase II study of VcR\u2010CVAD with maintenance rituximab for previously untreated mantle cell lymphoma","volume":"120","author":"Kahl B.S.","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-537555"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3803"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200920"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-541953"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-369629"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.041392"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-275305"},{"key":"e_1_2_11_68_1","first-page":"152","article-title":"Clinical, metabolic and molecular responses after 4 courses of R\u2010DHAP and after autologous stem cell transplantation for untreated mantle cell lymphoma patients included in the LyMa trial, a Lysa study","volume":"120","author":"Gouill S.","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402406"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388298"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.050203"},{"key":"e_1_2_11_73_1","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1182\/blood.V118.21.1647.1647","article-title":"Safety, tolerability and activity of ofatumumab, bendamustine and dexamethasone combination as first\u2010line treatment of Mantle\u2010cell lymphoma in the elderly: a multicenter study","volume":"118","author":"Magni M.","year":"2011","journal-title":"Blood"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2011.03.010"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386763"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08958.x"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.9585"},{"key":"e_1_2_11_78_1","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nm1290","article-title":"Vaccine\u2010induced tumor\u2010specific immunity despite severe B\u2010cell depletion in mantle cell lymphoma","volume":"11","author":"Neelapu S.S.","year":"2005","journal-title":"Nature Medicine"},{"key":"e_1_2_11_79_1","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1182\/blood.V116.21.3963.3963","article-title":"PILLAR\u20101: preliminary results of a phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to bortezomib","volume":"116","author":"O'Connor O.A.","year":"2010","journal-title":"Blood"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12819"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.036277"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1864"},{"key":"e_1_2_11_83_1","first-page":"56","article-title":"A phase I Study of the anti\u2010CD79b antibody\u2010drug conjugate (ADC) DCDS4501A targeting CD79b in relapsed or refractory B\u2010cell non\u2010Hodgkin's lymphoma (NHL)","volume":"120","author":"Palanca\u2010Wessels M.C.","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-189977"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.1.88"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2845"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-230250"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.053173"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0001"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1185-4"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08228.x"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08315.x"},{"key":"e_1_2_11_94_1","first-page":"43","article-title":"Phase I\u2010II study of bortezomib in combination with R\u2010HCVAD and R\u2010methotrexate\/cytarabine (R\u2010MA) in untreated mantle cell lymphoma (MCL)","volume":"96","author":"Romaguera J.","year":"2011","journal-title":"Haematologica"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00028-X"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.1142"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3907"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.8006"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_11_101_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.4251"},{"key":"e_1_2_11_102_1","first-page":"167","article-title":"Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma","volume":"3","author":"Samad N.","year":"2010","journal-title":"Onco Targets and Therapy"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk152"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2011.09.010"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.2444"},{"key":"e_1_2_11_106_1","first-page":"8519","article-title":"Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3\u2010kinase P110{delta} (PI3K{delta}), in patients with relapsed or refractory mantle cell lymphoma (MCL)","volume":"31","author":"Spurgeon S.E.F.","year":"2013","journal-title":"Journal of Clinical Oncology (ASCO Annual Meeting Abstracts)"},{"key":"e_1_2_11_107_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.6789"},{"key":"e_1_2_11_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-184200"},{"key":"e_1_2_11_109_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.9842"},{"key":"e_1_2_11_110_1","doi-asserted-by":"crossref","first-page":"8501","DOI":"10.1200\/jco.2013.31.15_suppl.8501","article-title":"Preliminary results of PI3K{delta} inhibitor idelalisib (GS\u20101101) treatment in combination with everolimus, bortezomib, or bendamustine\/rituximab in patients with previously treated mantle cell lymphoma (MCL)","volume":"31","author":"Wagner\u2010Johnston N.D.","year":"2013","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_11_111_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.8545"},{"key":"e_1_2_11_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70200-0"},{"key":"e_1_2_11_113_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_11_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12780"},{"key":"e_1_2_11_115_1","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1182\/blood.V87.11.4483.bloodjournal87114483","article-title":"Mantle cell lymphoma\u2013 an entity comes of age","volume":"87","author":"Weisenburger D.D.","year":"1996","journal-title":"Blood"},{"key":"e_1_2_11_116_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.4281"},{"key":"e_1_2_11_117_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-039859"},{"key":"e_1_2_11_118_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.466"},{"key":"e_1_2_11_119_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626"},{"key":"e_1_2_11_120_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.226"},{"key":"e_1_2_11_121_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.051813"},{"key":"e_1_2_11_122_1","doi-asserted-by":"crossref","first-page":"436s","DOI":"10.1200\/jco.2006.24.18_suppl.7560","article-title":"Sequential radioimmunotherapy with tositumomab\/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions","volume":"24","author":"Zelenetz A.D.","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_11_123_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23608"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13000","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T16:47:36Z","timestamp":1696265256000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,28]]},"references-count":122,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1111\/bjh.13000"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13000","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,28]]},"assertion":[{"value":"2014-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-05-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-06-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}